Does Androgen Deprivation Therapeutic Drugs Interact with Infliximab Dyyb?
CDI records a major classification for Androgen Deprivation Therapeutic Drugs and Infliximab Dyyb. The stored summary is: Therapeutic infectious agents not recommended concurrently with infliximab due to increased infection risk. The mechanism involves immunosuppression from tnf antagonism. Patients taking both medications should consult their healthcare provider before starting, stopping, or changing the dosage of either drug. This record was extracted from drug labeling through openFDA. NIH/NLM RxNorm is used for drug identities. The summary and severity classification are CDI's processed information, not a verbatim source quotation. Product, route, and patient circumstances matter.
- Severity
- Major
- Infliximab Dyyb Class
- Tumor Necrosis Factor Blocker
- Management
- Close medical supervision required
- Data Source
- U.S. FDA via OpenFDA
Recorded Mechanism
Immunosuppression from TNF antagonism
What To Tell Your Doctor or Pharmacist
If you are taking Androgen Deprivation Therapeutic Drugs and your doctor is considering prescribing Infliximab Dyyb (or vice versa), make sure to:
- Inform your doctor and pharmacist of all current medications, including over-the-counter drugs and supplements
- Ask whether the benefits of combining these medications outweigh the risks for your specific situation
- Ask what symptoms to watch for that would indicate the interaction is causing problems
- Ask how frequently you should be monitored while these are co-prescribed
- Ask whether any dosage adjustments are needed
- Never stop or change either medication without first consulting your healthcare provider